127 related articles for article (PubMed ID: 24783898)
1. Anti-rods and rings autoantibodies can occur in the hepatitis c-naïve population.
Shaikh Y; Krantz A; El-Farra Y
J Prev Med Hyg; 2013 Sep; 54(3):175-80. PubMed ID: 24783898
[TBL] [Abstract][Full Text] [Related]
2. Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery.
Calise SJ; Chan EKL
Autoimmun Rev; 2020 Oct; 19(10):102643. PubMed ID: 32805424
[TBL] [Abstract][Full Text] [Related]
3. Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014.
Dillon CF; Weisman MH; Miller FW
PLoS One; 2020; 15(1):e0226516. PubMed ID: 31929535
[TBL] [Abstract][Full Text] [Related]
4. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C.
Probst C; Radzimski C; Blöcker IM; Teegen B; Bogdanos DP; Stöcker W; Komorowski L
Clin Chim Acta; 2013 Mar; 418():91-6. PubMed ID: 23333419
[TBL] [Abstract][Full Text] [Related]
5. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.
Stinton LM; Myers RP; Coffin CS; Fritzler MJ
BMC Gastroenterol; 2013 Mar; 13():50. PubMed ID: 23506439
[TBL] [Abstract][Full Text] [Related]
6. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
Keppeke GD; Calise SJ; Chan EK; Andrade LE
World J Gastroenterol; 2016 Feb; 22(6):1966-74. PubMed ID: 26877604
[TBL] [Abstract][Full Text] [Related]
7. Association of Autoantibody to Rods and Rings with Hepatitis C Outcome and Viral Load.
Dhaouadi T; Abdellatif J; Jallouli M; Mejdoubi M; Sfar I; Mouelhi L; Aouini S; Ben Abdallah T; Gorgi Y
Viral Immunol; 2019 Jun; 32(5):214-220. PubMed ID: 31081724
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to intracellular "rods and rings" structures in two patients with autoimmune hepatitis treated with azathioprine.
Galaski J; Koop AC; Lütgehetmann M; Lohse AW; Weiler-Normann C
Autoimmunity; 2020 Sep; 53(6):362-365. PubMed ID: 32662301
[No Abstract] [Full Text] [Related]
9. Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.
Dammermann W; Polywka S; Dettmann I; Mindorf S; Komorowski L; Wehmeyer M; Schulze Zur Wiesch J; Stöcker W; Lüth S
Med Microbiol Immunol; 2017 Oct; 206(5):379-382. PubMed ID: 28815296
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
11. Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.
da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
Immunol Res; 2018 Oct; 66(5):605-610. PubMed ID: 30220012
[TBL] [Abstract][Full Text] [Related]
12. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
Wu CH; Xu XY; Tian GS; Yu YY
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
[TBL] [Abstract][Full Text] [Related]
13. Anti-rods/rings: a human model of drug-induced autoantibody generation.
Calise SJ; Keppeke GD; Andrade LE; Chan EK
Front Immunol; 2015; 6():41. PubMed ID: 25699057
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Covini G; Carcamo WC; Bredi E; von Mühlen CA; Colombo M; Chan EK
Antivir Ther; 2012; 17(5):805-11. PubMed ID: 22293655
[TBL] [Abstract][Full Text] [Related]
15. Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies.
Keppeke GD; Prado MS; Nunes E; Perazzio SF; Rodrigues SH; Ferraz ML; Chan EK; Andrade LE
Clin Immunol; 2016 Dec; 173():149-156. PubMed ID: 27746381
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China.
Bai L; Feng ZR; Lu HY; Li WG; Yu M; Xu XY
Chin Med J (Engl); 2009 Jan; 122(1):5-9. PubMed ID: 19187609
[TBL] [Abstract][Full Text] [Related]
17. Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection.
Calise SJ; Bizzaro N; Nguyen T; Bassetti D; Porcelli B; Almi P; Barberio G; Pesce G; Satoh M; Chan EK
Auto Immun Highlights; 2016 Dec; 7(1):15. PubMed ID: 27844412
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile.
Williams MJ; Lawson A; Neal KR; Ryder SD; Irving WL;
J Viral Hepat; 2009 May; 16(5):325-31. PubMed ID: 19302340
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of autoantibody and its relationship with genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection.
Kirdar S; Sener AG; Cengİz M; Aydin N
APMIS; 2016 Nov; 124(11):979-984. PubMed ID: 27670736
[TBL] [Abstract][Full Text] [Related]
20. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.
Carcamo WC; Ceribelli A; Calise SJ; Krueger C; Liu C; Daves M; Villalta D; Bizzaro N; Satoh M; Chan EK
J Clin Immunol; 2013 Feb; 33(2):420-6. PubMed ID: 23100146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
